<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00821665</url>
  </required_header>
  <id_info>
    <org_study_id>07-3-004</org_study_id>
    <nct_id>NCT00821665</nct_id>
  </id_info>
  <brief_title>Blood Glucose Homeostasis in Type 2 Diabetes: the Effects of Saccharose</brief_title>
  <official_title>Blood Glucose Homeostasis in Type 2 Diabetes: the Effects of Saccharose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Suikerstichting Nederland (Baarn)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyperglycemia forms a direct and independent risk factor for the development of
      cardiovascular co-morbidities in type 2 diabetes. Consumption of sucrose-sweetened soft
      drinks might further increase the prevalence of hyperglycemic episodes.

      The objective of the study was to assess glycemic control in type 2 diabetes patients and
      healthy lean and obese controls under strict dietary standardization but otherwise free
      living conditions, with and without the consumption of soft drinks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hyperglycemia</measure>
    <time_frame>24h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hyperglycemia</measure>
    <time_frame>Postprandially</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Glycemic Control</condition>
  <arm_group>
    <arm_group_label>Sucrose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sucrose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Water</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Water</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sucrose consumption</intervention_name>
    <description>Sucrose</description>
    <arm_group_label>Sucrose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>water consumption</intervention_name>
    <description>water</description>
    <arm_group_label>Water</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Lean NGT Group

          -  Normoglycemic (according to 2006 ADA guidelines)

          -  BMI &lt; 27 kg/m2

        Obese NGT Group

          -  Normoglycemic

          -  BMI 30- 35 kg/m2

        Obese type 2 diabetes Group

          -  BMI 30- 35 kg/m2

          -  Oral blood glucose lowering medication

        Exclusion Criteria:

          -  Exogenous insulin use

          -  Cardiac disease (any cardiac event in the last 5 years)

          -  HbA1c &gt;10%

          -  Microalbuminuria: albumin:creatinine ratio &gt;2,5
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luc J van Loon, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University</name>
      <address>
        <city>Maastricht</city>
        <state>Limbrug</state>
        <zip>6200 MD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2009</study_first_submitted>
  <study_first_submitted_qc>January 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2009</study_first_posted>
  <last_update_submitted>January 12, 2009</last_update_submitted>
  <last_update_submitted_qc>January 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. L.J.C. van Loon Ph.D</name_title>
    <organization>Maastricht University</organization>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Glycemic control</keyword>
  <keyword>(postprandial) Hyperglycemia</keyword>
  <keyword>Sucrose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

